Gufic Biosciences Q1 FY27 Earnings Call: Revenue 260.8 Cr, EBITDA Margin at 18%
GUFICBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Q1 FY27 revenue rose to INR 260.8 cr from INR 226.9 cr YoY (about 15% growth). EBITDA jumped to INR 47.2 cr with margin expanding to 18.09% from 14.6%. PAT nearly doubled to INR 22.46 cr. Management guides 15-20% YoY growth, sees 18% margin as starting point for further improvement. Indore plant capacity utilization targeted at 40-45% by year-end. New tie-ups with CHAI for liposomal amphotericin B and Prollenium for fillers. Peak revenue potential without further capex seen at INR 1,600-1,800 cr.
Strong quarterly numbers with margin expansion and clear growth roadmap. Indore capacity ramp-up, international IP-led model, and new product launches are key catalysts ahead.